- Home
- EEX vs AUPH Comparison
EEX vs AUPH Comparison
Compare EEX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEX
- AUPH
- Stock Information
- Founded
- EEX 2013
- AUPH 1993
- Country
- EEX United States
- AUPH Canada
- Employees
- EEX N/A
- AUPH N/A
- Industry
- EEX Advertising
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- EEX Consumer Discretionary
- AUPH Health Care
- Exchange
- EEX Nasdaq
- AUPH Nasdaq
- Market Cap
- EEX 910.8M
- AUPH 1.1B
- IPO Year
- EEX 2017
- AUPH 1999
- Fundamental
- Price
- EEX $5.44
- AUPH $7.58
- Analyst Decision
- EEX Strong Buy
- AUPH Strong Buy
- Analyst Count
- EEX 2
- AUPH 2
- Target Price
- EEX $7.90
- AUPH $11.50
- AVG Volume (30 Days)
- EEX 105.7K
- AUPH 1.6M
- Earning Date
- EEX 08-06-2025
- AUPH 07-31-2025
- Dividend Yield
- EEX 1.13%
- AUPH N/A
- EPS Growth
- EEX N/A
- AUPH N/A
- EPS
- EEX 0.02
- AUPH 0.27
- Revenue
- EEX $413,100,000.00
- AUPH $247,295,000.00
- Revenue This Year
- EEX $14.85
- AUPH $12.15
- Revenue Next Year
- EEX $6.42
- AUPH $18.31
- P/E Ratio
- EEX $215.37
- AUPH $28.53
- Revenue Growth
- EEX 4.87
- AUPH 29.20
- 52 Week Low
- EEX $3.22
- AUPH $5.20
- 52 Week High
- EEX $6.65
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- EEX 73.43
- AUPH 40.36
- Support Level
- EEX $4.80
- AUPH $7.29
- Resistance Level
- EEX $5.00
- AUPH $8.86
- Average True Range (ATR)
- EEX 0.14
- AUPH 0.34
- MACD
- EEX 0.02
- AUPH -0.06
- Stochastic Oscillator
- EEX 100.00
- AUPH 19.37
About EEX Emerald Holding Inc.
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.